Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.

被引：0
|
作者：
Kambhampati, Swetha
Saumoy, Monica
Pak, Stacy
Budde, L. Elizabeth
Mei, Matthew Genyeh
Popplewell, Leslie
Wen, Yi-Ping
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Herrera, Alex Francisco
Thiruvengadam, Nikhil
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Penn Med Princeton Med Ctr, Plainsboro, NJ USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Texas MD Anderson Canc Ctr Chairman, Houston, TX USA
[6] Loma Linda Univ, Loma Linda, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7568
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
    Corcoran, Sean R.
    Phelan, James D.
    Choi, Jaewoo
    Shevchenko, Galina
    Fenner, Rachel E.
    Yu, Xin
    Scheich, Sebastian
    Hsiao, Tony
    Morris, Vivian M.
    Papachristou, Evangelia K.
    Kishore, Kamal
    D'Santos, Clive S.
    Ji, Yanlong
    Pittaluga, Stefania
    Wright, George W.
    Urlaub, Henning
    Pan, Kuan-Ting
    Oellerich, Thomas
    Muppidi, Jagan
    Hodson, Daniel J.
    Staudt, Louis M.
    CANCER DISCOVERY, 2024, 14 (09) : 1653 - 1674
  • [42] Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Ghione, Paola
    Salles, Gilles
    HAEMATOLOGICA, 2024, 109 (09) : 2802 - 2809
  • [43] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [44] Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
    Qi, Hui
    Wang, Fuyang
    Han, Bingrui
    Wang, Xiaomin
    Qiang, Xiangnan
    Zhang, Zhixiang
    Gu, Qiangyang
    CANCER RESEARCH, 2023, 83 (07)
  • [45] Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients
    Ren, Yuhong
    Zhuang, Jingli
    Yuan, Ling
    Ji, Lili
    Ke, Yang
    Liu, Peng
    BLOOD, 2023, 142
  • [46] Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
    Shemesh, Colby S.
    Agarwal, Priya
    Lu, Tong
    Lee, Calvin
    Dere, Randall C.
    Li, Xiaobin
    Li, Chunze
    Jin, Jin Y.
    Girish, Sandhya
    Miles, Dale
    Lu, Dan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 831 - 842
  • [47] Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the Standardof-Care Setting: A Single-Center Experience
    Khadka, Sushmita
    Dong, Ning
    Chavez, Julio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S480 - S480
  • [48] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
    Bartlett, Nancy L.
    Chen, Andy I.
    Kolibaba, Kathryn S.
    Lamy, Thierry
    Jones, Surai
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [49] Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
    Colby S. Shemesh
    Priya Agarwal
    Tong Lu
    Calvin Lee
    Randall C. Dere
    Xiaobin Li
    Chunze Li
    Jin Y. Jin
    Sandhya Girish
    Dale Miles
    Dan Lu
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 831 - 842
  • [50] Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
    Cooper, Keith
    Maund, Emma
    Takahashi, Marcia Tomie
    Shepherd, Jonathan
    PHARMACOECONOMICS, 2024, 42 (11) : 1177 - 1179
12345